{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:44:13Z","timestamp":1780602253824,"version":"3.54.1"},"reference-count":23,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,7,13]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Sweet syndrome (SS), also referred as acute febrile neutrophilic dermatosis, is an inflammatory process characterised by the abrupt appearance of erythematous papules or nodules with predominant neutrophilic infiltration in the dermis. Fever and neutrophilia are common presenting features. However, extracellular manifestations, including ocular and musculoskeletal, may occur. SS is divided into three subtypes: classical (or idiopathic), malignancy associated and drug induced. Medication-induced subtype accounts for up to 26% of cases. In recent years, emerging evidence has showed that SS may also occur in neutropenic patients who underwent induction for acute myeloid leukemia (AML). The identification of FMS-like tyrosine kinase 3 (FLT3) gene mutation in approximately 30% of patients with AML has promoted the targeted therapy with FLT3-internal tandem duplication (ITD) inhibitors. Midostaurin, a recently Food and Drug Administration-approved medication for FLT3-ITD-positive AML, was reported once as cause for SS. We report a midostaurin-induced SS with neutropenia in a patient following induction chemotherapy of AML<\/jats:p>","DOI":"10.1136\/bcr-2021-243615","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T12:14:05Z","timestamp":1629461645000},"page":"e243615","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-8854","authenticated-orcid":false,"given":"Samer","family":"Alkassis","sequence":"first","affiliation":[{"name":"Internal Medicine, Detroit Medical Center, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Rizwan","sequence":"additional","affiliation":[{"name":"Internal Medicine, Detroit Medical Center, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Daoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The Hashemite University, Zarqa, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chi","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"2025082802505744000_14.8.e243615.1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-34"},{"key":"2025082802505744000_14.8.e243615.2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3892\/ijo.2013.1874","article-title":"Insight into sweet's syndrome and associated-malignancy: a review of the current literature","volume":"42","author":"Raza","year":"2013","journal-title":"Int J Oncol"},{"key":"2025082802505744000_14.8.e243615.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1902"},{"key":"2025082802505744000_14.8.e243615.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782292"},{"key":"2025082802505744000_14.8.e243615.5","doi-asserted-by":"crossref","unstructured":"Kaur A , Jacobs MS , Raza S . Characteristics of sweet\u2019s syndrome associated with novel acute myeloid leukemia targeted drugs\u2014midostaurin and enasidenib. Advances In Cell And Gene Therapy 2019;2.doi:10.1002\/acg2.61","DOI":"10.1002\/acg2.61"},{"key":"2025082802505744000_14.8.e243615.6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jdcr.2020.07.043","article-title":"Lamotrigine-induced sweet syndrome: possible new drug association","volume":"6","author":"Neely","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2025082802505744000_14.8.e243615.7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3904\/kjim.2001.16.3.218","article-title":"Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid","volume":"16","author":"Park","year":"2001","journal-title":"Korean J Intern Med"},{"key":"2025082802505744000_14.8.e243615.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01996.x"},{"key":"2025082802505744000_14.8.e243615.9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ad.2015.12.001","article-title":"Sweet syndrome: a review and update","volume":"107","author":"Villarreal-Villarreal","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"2025082802505744000_14.8.e243615.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1201-z"},{"key":"2025082802505744000_14.8.e243615.11","unstructured":"Sweet syndrome (acute febrile neutrophilic dermatosis): pathogenesis, clinical manifestations, and diagnosis [Internet], 2020. Available: https:\/\/www.uptodate.com\/contents\/sweet-syndrome-acute-febrile-neutrophilic-dermatosis-pathogenesis-clinical-manifestations-and-diagnosis?search=sweet%20syndrome&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 [Accessed 05 Apr 2021]."},{"key":"2025082802505744000_14.8.e243615.12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/20009666.2020.1766818","article-title":"Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor","volume":"10","author":"Paudel","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2025082802505744000_14.8.e243615.13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamadermatol.2015.6121","article-title":"FLT3 inhibitor-associated neutrophilic dermatoses","volume":"152","author":"Varadarajan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025082802505744000_14.8.e243615.14","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719827310"},{"key":"2025082802505744000_14.8.e243615.15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614359"},{"key":"2025082802505744000_14.8.e243615.16","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000606"},{"key":"2025082802505744000_14.8.e243615.17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.12998\/wjcc.v3.i2.196","article-title":"Sweet syndrome and differentiation syndrome in a patient with acute promyelocytic leukemia","volume":"3","author":"Solano-L\u00f3pez","year":"2015","journal-title":"World J Clin Cases"},{"key":"2025082802505744000_14.8.e243615.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168617"},{"key":"2025082802505744000_14.8.e243615.19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082802505744000_14.8.e243615.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08325.x"},{"key":"2025082802505744000_14.8.e243615.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the pathogenesis of sweet's syndrome","volume":"10","author":"Heath","year":"2019","journal-title":"Front Immunol"},{"key":"2025082802505744000_14.8.e243615.22","doi-asserted-by":"publisher","DOI":"10.1159\/000068462"},{"key":"2025082802505744000_14.8.e243615.23","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203020-00005"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:51:05Z","timestamp":1756374665000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,20]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bcr-2021-243615"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243615","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}